• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Kewaunee Scientific Corporation

    5/9/25 10:54:08 AM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    SD 1 cy2024formsdconflictminera.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _________________________
    FORM SD
    _________________________
    Specialized Disclosure Report
    _________________________
    KEWAUNEE SCIENTIFIC CORPORATION
    (Exact name of registrant as specified in its charter)
    _________________________
    Delaware0-5286 38-0715562
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number) (IRS Employer
    Identification No.)
    2700 West Front Street
    Statesville, North Carolina
     28677-2927
    (Address of principal executive offices) (Zip Code)

    Donald T. Gardner III; 704-873-7202
    (Name and telephone number, including area code, of the person to contact in connection with this disclosure.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ☒ Rule 13p-1 under the Securities Exchange Act (17CFR 240.13p-1) for the disclosure period from January 1 to December 31, 2024.
    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ____.
            




    Section 1 - Conflict Minerals Disclosure

    Item 1.01    Conflict Minerals Disclosure and Report

    Kewaunee Scientific Corporation shares the concerns of Congress and the international business community that profits from the mining of certain minerals (“3TGs,” as defined below) in the Democratic Republic of Congo or its adjoining countries may be aiding human rights abuses. The term “3TGs” refers to columbite-tantalite (coltan), cassiterite, gold, wolframite or their derivatives, which are limited to tantalum, tin and tungsten.

    With respect to the calendar year ended December 31, 2024, we identified several of our products for which 3TGs (as defined above) may be present in and necessary to their functionality or production. Accordingly, we have developed a conflict minerals procedure, as described below, reasonably designed to identify whether the 3TGs in the Covered Products, if any, originated in the Democratic Republic of Congo or an adjoining country (the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia or Angola) (the “Covered Countries”), or whether any of the 3TGs in the Covered Countries are from recycled or scrap sources.

    On an annual basis, our product development team reviews a list of our significant vendors and identifies any vendors for which the materials we purchase may contain 3TGs. Through this process, we determined that several of our products may contain small traces of one or more 3TGs. As a result, we have established a process whereby we conduct a country-of-origin inquiry reasonably designed to determine whether 3TGs contained in or used to produce these products, if any, originated in a Covered Country or were from recycled or scrap sources.

    Description of the Company’s Reasonable Country of Origin Inquiry

    To determine the origin of any 3TGs, a survey was sent to all of our identified suppliers whose products may contain them. The survey inquired about the origin of their 3TGs and whether they had a written policy for conflict-free sourcing of 3TGs, among other items. Except as described below, responses received from the survey indicated that any 3TGs in materials provided by our suppliers did not originate from the Covered Countries. In addition to the responses received from our suppliers, management has no reason to believe that any 3TGs in or used in the production of our Covered Products may have originated in the Covered Countries.

    In response to our survey, one supplier identified one potential smelter located in a Covered Country. We have determined that this potential smelter is listed as “Conformant” for having successfully completed an assessment against the applicable Responsible Minerals Initiative Responsible Minerals Assurance Process assessment standard. Our inquiry regarding the origin or source of 3TG contained in our products did not provide sufficient information to conclusively determine the country of origin of 3TG contained in our products that we obtain from this supplier or whether such 3TG came from recycled or scrap sources, or whether the 3TG benefited or financed armed groups, and we cannot ascertain if a Covered Country source was in fact used for the 3TG contained in any of our products containing 3TGs from this supplier.

    If at any time we discover the use of any 3TGs originating from the Covered Countries, we will take appropriate measures to discontinue use of such materials or processes.

    This information is also available on our website at www.kewaunee.com, as well as the SEC’s EDGAR database at www.sec.gov.



    Signature

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this disclosure to be signed on its behalf by the undersigned hereunto duly authorized.

     KEWAUNEE SCIENTIFIC CORPORATION
                                 (Registrant)
    Date: May 9, 2025 By/s/ Donald T. Gardner III
     Donald T. Gardner III
     Vice President, Finance and
    Chief Financial Officer

    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials